Is ALS as Common in Females as It Is in Males?

ALS is not equally common in men and women. Men develop the disease roughly 1.3 times more often than women, according to large pooled analyses of incidence data from around the world. That gap is real but smaller than many people assume, and it does not stay constant across the lifespan. After menopause, the difference between the sexes shrinks considerably, which has pushed researchers toward hormonal explanations. But the story runs deeper than hormones alone, touching on genetics, immune biology, and even how the disease presents and progresses differently depending on sex.

How Big Is the Gap, Really?

A dose-response meta-analysis pooling data across multiple countries found the overall male-to-female ratio for ALS incidence to be about 1.33 when using crude incidence rates, and about 1.35 after standardizing for age.¹ In practical terms, for every three women diagnosed with ALS, roughly four men receive the same diagnosis. That is a meaningful difference epidemiologically, but it is far from the dramatic skew you see in some other neurological conditions.

A more recent systematic review confirmed this overall picture, placing the sex ratio at about 1.25, and made an important distinction. The male excess exists almost entirely within sporadic ALS, the form that arises without a clear family history. For familial ALS, the ratio was essentially 1-to-1.² That split is a strong clue. If the inherited form of the disease affects men and women equally, the male predominance in sporadic ALS probably comes from something environmental, hormonal, or related to sex-specific biology rather than from the core disease mechanism itself.

The Menopause Shift

One of the most striking patterns in ALS epidemiology is how the sex ratio changes with age. In younger adults, men outnumber women among ALS patients by a wide margin. Population-based data from registries in England and Italy show that before the typical age of menopause, the male-to-female ratio exceeds 2.5. After menopause, it drops below 1.5.³ The proportion of women among ALS patients rose from about 30% in the younger group to nearly 44% in the older group, and that difference was statistically significant.

This age-related convergence has naturally pointed investigators toward estrogen as a possible protective factor. If women are relatively protected during their reproductive years and then lose that protection after menopause, it would neatly explain why the sex gap narrows in older cohorts. The evidence from reproductive history backs this up. Data from the U.S. National ALS Registry showed that women who completed menopause before age 50, meaning they lost estrogen exposure earlier, were about 80% more likely to be diagnosed with ALS before age 60 compared to women who went through menopause later. Their average age at ALS diagnosis was roughly six years earlier.⁴

What Estrogen Appears to Do

Animal studies provide more direct evidence for estrogen’s neuroprotective role in ALS. In mice carrying a common ALS-related gene mutation, removing the ovaries (which eliminates most estrogen production) significantly accelerated disease progression. When researchers then gave those ovariectomized mice estradiol, the main form of estrogen, it delayed disease progression and rescued their lifespan back to what would be expected in intact female mice.⁵ A separate study using the same mouse model confirmed that estrogen treatment did not delay disease onset itself but did slow the progression of motor dysfunction and extend survival after ovariectomy.⁶

At the cellular level, researchers have shown that motor neurons in the spinal cord have estrogen receptors and that estradiol activates an anti-cell-death signaling pathway in those cells. Estradiol also protected motor neurons when they were exposed to inflammatory signals that mimic the kind of damage seen in ALS.⁷ So there is a plausible chain: estrogen binds to motor neurons, activates protective pathways, and slows cell death. When estrogen declines after menopause, that protection weakens.

The picture is not as clean as it sounds, though. Studies looking at the relationship between endogenous estrogen exposure and ALS risk in women have produced conflicting results when using reproductive markers like age at first period or number of pregnancies as proxies.⁸ The menopause connection is the most consistent finding, but the broader hormonal story is still being worked out.

It Is Not Just Estrogen

Given the menopause data, you might wonder whether testosterone or androgen receptors explain the male side of the equation. Researchers tested this directly in ALS mice by deleting the androgen receptor from nerve cells and, separately, by overexpressing it. Neither manipulation had any meaningful effect on disease onset, progression, or survival.⁹ That result is important because it rules out the simplest version of the “male hormones are bad for motor neurons” hypothesis. The sex difference in ALS is not a mirror image where estrogen protects and testosterone harms. Other mechanisms must be involved.

One candidate is neuroinflammation. The brain’s resident immune cells, microglia, behave differently in male and female ALS mice. Deleting a specific inflammatory receptor on microglia at the time of symptom onset extended survival in male mice but not in female mice.¹⁰ This suggests that the inflammatory pathways driving neurodegeneration in ALS are not identical between men and women, which carries real implications for treatment design.

Genetic Mutations Show Their Own Sex Patterns

When specific gene mutations are tracked across ALS populations, some interesting sex-linked patterns emerge. The most common genetic cause of ALS is a repeat expansion in the C9orf72 gene. A meta-analysis of over 12,000 ALS patients found that women carrying this mutation were slightly overrepresented compared to men, with about a 16% higher prevalence among female ALS patients.¹¹ In other words, while ALS in general leans male, the C9orf72-associated form leans slightly female.

Carrying C9orf72 also affects men and women differently in terms of prognosis. In a large multicenter study, the mutation was an independent risk factor for shorter survival in men but not in women.¹² Meanwhile, for SOD1 mutations, a different picture emerged. In one study of SOD1-mutant ALS patients, there was no significant difference between men and women in age at disease onset.¹³ But a Spanish cohort carrying a specific SOD1 mutation found that female sex was independently associated with faster disease progression, with women surviving a median of about 236 months compared to 301 months for men with that same mutation.¹⁴ The takeaway is that the relationship between sex and ALS outcomes depends heavily on which genetic subtype is involved. Generalizations about “men do worse” or “women do better” collapse when you drill into specific mutations.

How ALS Looks Different in Men and Women

Beyond the raw numbers, the disease itself does not present identically in both sexes. In sporadic ALS, men are more likely to develop initial weakness in the limbs (spinal onset), while women more often begin with speech and swallowing difficulties (bulbar onset).¹⁵ This distinction matters clinically because bulbar-onset ALS tends to carry a worse prognosis and affects daily functioning differently from the limb-onset form.

Among people who develop ALS later in life, the sex differences in presentation become even more pronounced. A study of late-onset ALS found that older women had more bulbar-onset disease and significantly lower body mass index at diagnosis, while older men were more likely to already have bulbar and respiratory symptoms at their first clinical exam, along with lower lung capacity measurements.¹⁶ These are not trivial differences. They affect everything from which specialists a patient sees first to how quickly the diagnosis is made.

Survival and Progression Are Not the Same Thing

Here is where the sex differences in ALS get counterintuitive. Men generally have shorter survival times. When stratified by onset site, men with spinal-onset ALS had about a 20% higher risk of death, and men with bulbar-onset ALS had about a 36% higher risk, compared to women with the same form.¹⁷ Yet women showed steeper functional decline on standardized assessment scales regardless of where the disease started. Men, on the other hand, showed faster respiratory decline and quicker weight loss. So men die sooner, but women lose day-to-day function faster. These are measuring different dimensions of the same disease.

The cognitive side adds another layer. A systematic review and meta-analysis found that female sex was associated with greater susceptibility to executive cognitive impairment in ALS, with roughly 80% higher odds compared to men.¹⁸ Lower estrogen levels in women with ALS have also been linked to worse verbal fluency scores and more behavioral changes, particularly in patients with bulbar onset.¹⁹ So while women may survive longer on average, they may face a heavier cognitive burden during the course of the disease.

Environmental Exposures and the Confounding of Sex with Lifestyle

Part of the male excess in ALS may have nothing to do with biology and everything to do with what men are more likely to encounter in their lives. Military service is one well-studied example. A prospective study found that men who served in the military had about a 53% higher rate of death from ALS compared to men who had not served, and this elevation held across every branch except the Marines (where the sample was small).²⁰ Because military service has historically been overwhelmingly male, this could inflate the apparent sex ratio without reflecting any intrinsic biological vulnerability in men.

Occupational exposures to heavy metals, pesticides, and intense physical exertion have also been investigated as ALS risk factors, and these exposures disproportionately affect men in most societies. Untangling whether the male predominance comes from biological susceptibility, environmental exposure, or some interaction of the two is one of the harder problems in ALS epidemiology. The fact that the sex ratio has been gradually narrowing over time in many countries, as women’s occupational exposures and lifestyle patterns converge with men’s, suggests that environment plays a nontrivial role.

Metabolic Differences That Affect Prognosis

ALS is increasingly understood as a disease with a major metabolic component. Many patients develop hypermetabolism, burning calories at an abnormally high rate, which leads to weight loss and worse outcomes. Research on blood lipid profiles has revealed sex-specific patterns. High HDL cholesterol predicted poor prognosis across all ALS patients, but low LDL cholesterol was a risk factor for worse outcomes only in women.²¹ This is the kind of finding that could eventually inform sex-specific clinical monitoring. Lipid panels are cheap and routine, and knowing that a particular pattern carries different implications for a woman with ALS than for a man could help guide nutritional interventions.

Gaps in Treatment and Care

Sex differences in ALS extend into how patients are treated, though the evidence here is thinner. A Swedish study found that men were significantly overrepresented among ALS patients receiving mechanical ventilation, with a male-to-female ratio of 2.3-to-1, which exceeded the expected ratio based on the sex distribution of ALS in the population.²² Once on ventilation, though, there were no significant differences in pulmonary function, blood gas measurements, or survival between men and women. The disparity seems to be about who gets offered or agrees to ventilation, not about who benefits from it.

Whether referral patterns contribute to the sex ratio in ALS registries is also worth asking. A study examining referral bias across four European regions found that male percentages were broadly similar between population-based ALS cases and referral-center cohorts, though one region (Puglia, Italy) showed a noticeable gap where men were overrepresented in the population data compared to referral data.²³ Referral bias alone does not explain the sex ratio, but it is a reminder that the numbers we see in clinical registries are shaped partly by who shows up at specialty centers.

Why Sex-Specific ALS Research Still Lags

Despite the growing body of evidence that ALS behaves differently in men and women at nearly every level, from incidence to molecular pathways to clinical trajectory, most major clinical trials have not been designed to analyze sex as a primary variable. Historically, ALS trials have been underpowered for subgroup analyses by sex, and preclinical research using ALS mouse models has often relied disproportionately on male animals. The neuroinflammation findings described earlier, where a genetic intervention helped male mice but not females, illustrate why this matters. A drug that works through that pathway might succeed in men and fail in women, but if the trial pools everyone together, the result could be a wash that leads the treatment to be abandoned.

The sex-specific lipid findings, the C9orf72 prevalence differences, the divergent progression patterns, and the estrogen data all point toward the same conclusion: treating ALS as a single disease with one prognosis and one optimal treatment strategy ignores meaningful biological variation. Whether that recognition will eventually translate into sex-stratified clinical trials or sex-informed treatment protocols remains one of the open questions in the field.